Objectives: Loeys-Dietz syndrome (LDS) is an aggressive connective tissue disorder associated with increased risk of aortic dissection and aneurysm rupture at an early age and smaller aortic diameters. We report our experience with LDS to better understand its natural history and treatment outcomes and help establish treatment guidelines.
Intermediate-term outcomes of prophylactic aortic surgery for Loeys-Dietz syndrome (LDS) are excellent. Surgical reintervention remains common, particularly after aortic dissections. Early prophylactic surgery and close surveillance of the distal aorta in LDS patients, both with and without dissection, are necessary to achieve a good long-term prognosis.
See Editorial page 451.
See Editorial Commentary page 453.
Connective tissue disorders are increasingly being recognized and studied for their cardiovascular consequences. 1 It is incumbent on cardiologists and surgeons to better understand and manage patients with connective tissue disorders, particularly the more recently defined ones, such as LoeysDietz syndrome (LDS). LDS was identified in 2005 as an autosomal-dominant connective tissue disorder caused by mutation in transforming growth factor b receptor-1 (TGFBR1) and transforming growth factor b receptor-2 (TGFBR2) genes. Phenotypically, LDS is characterized by aortic aneurysms with generalized arterial tortuosity, cardiomyopathy, skin laxity and translucency, hypermobility, hypertelorism, pectus, craniosynostosis, and bifid or broad uvula or cleft palate. [1] [2] [3] After the initial description of LDS, gene mutations in SMAD3, transforming growth factor b2 ligand 2 and 3 (TGFB2 and TGFB3) were also noted to present with phenotypical features of LDS, particularly a very aggressive vascular disease. [4] [5] [6] [7] [8] [9] [10] There is a wide spectrum of clinical variability and heterogeneity of aortic involvement among individuals with these gene defects. Extensive basic and clinical research on LDS has resulted in a better understanding of its genetic basis, clinical manifestations, classification, and treatment recommendations. 1 There is a paucity of data regarding the surgical outcomes of patients with LDS. We report our experience with LDS to clarify its natural history and outcomes of surgical intervention, and to help establish treatment guidelines for patients with LDS.
PATIENTS AND METHODS
During the past decade, we developed a registry of patients with LDS at the Aorta Center in the Heart and Vascular Institute at Cleveland Clinic. We performed a retrospective review of all patients entered in this registry before April 24, 2017 (Figure 1 ). Entry into the study was based on genetically confirmed diagnosis of LDS and the patient establishing care at our institution for either medical management or surgical treatment. Some of these patients were evaluated and treated before the confirmed diagnosis of LDS. Later genetic testing and confirmation of phenotypic features established their diagnosis. Some patients had previous surgical interventions at other institutions.
For this report, the first surgical procedure performed at our institution was considered the index operation. Conduct of this study was approved by the Cleveland Clinic Institutional Review Board, with patient consent waived.
Patients are classified into 2 groups based on their treatment history. The aortic surgery group consists of those who underwent aortic surgery either at our or an outside institution. The non-aortic surgery group includes patients who did not undergo any aortic surgical procedure in their lifetime and were treated medically with ongoing clinical and radiologic surveillance. Two patients in this group had nonaortic cardiac operations performed at another institution, including an atrial septal defect repair in 1 patient and ligation of patent ductus arteriosus in another. The mainstay of medical treatment consists of aggressive blood pressure control using angiotensin receptor blockers or angiotensin-converting enzyme inhibitors and b-blockers to minimize the aortic wall stress affected by the velocity of ventricular contraction (dP/dT). Clinical and radiologic surveillance includes yearly computed tomographic angiography (CTA) combined with echocardiography or magnetic resonance imaging/angiography (MRI/MRA) to assess valvular function and the entire arterial tree from the neck through the pelvis. Additional imaging was performed as needed in patients requiring surgery. The threshold of aortic size greater than 4.2 cm or rate of growth greater than 0.5 cm/year was used as an indication for surgical intervention, per the guidelines for managing patients with LDS.
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Endpoints
Primary endpoints were postoperative in-hospital morbidity and mortality. Secondary endpoints were aorta-related reoperations and long-term mortality.
Data Collection, Patient Variables, and Statistics
Clinical information was extracted from hospital medical records, operative reports, discharge summaries, and outpatient clinic records. Data included patient demographics, gene mutation, medical and surgical history, family history of aortic disease, preoperative cardiovascular imaging, including echocardiogram, computed tomography, MRI/MRA, LDS phenotypic abnormalities, surgical indications and operative details, major postoperative complications, need for reoperation, acute dissection, and death.
Categorical variables are summarized as n (%), and continuous variables are summarized as median with first (Q1) and third (Q3) quartiles or mean AE standard deviation. Survival and freedom from intervention were determined using the Kaplan-Meier method. The Wilcoxon chi-squared statistic was computed to test differences between groups, and P < .05 was considered statistically significant. Statistical analysis was performed using JMP Pro 13.0 (SAS Institute, Inc., Cary, NC).
Follow-up Data
Follow-up data were obtained from clinic visits, review of medical records, and imaging. Follow-up was 100% complete, with data being collected through the latest follow-up visit.
Operative Technique
Our operative technique for aortic root replacement, including an L.G.S.-modified valve-sparing root reimplantation using pledgets, sizing according to body surface area, and Hegar dilators, has been described previously. 12 For the composite valve-graft root replacement, we used a standard technique of root replacement with coronary button implantation. In some reoperations, an 8-mm graft to the left main coronary artery was used. Circulatory arrest was used for aortic arch replacement, and separate bypasses were created for the individual arch branch vessels to minimize late risk of patch aneurysms. Our technique for total arch replacement with elephant trunk, brain protection, and second-stage elephant trunk completion has been described previously. 13, 14 In addition, our technique for descending thoracic aortic and thoracoabdominal aortic replacement has been published previously. 15 A commercially available, 4-branched graft was used for thoracoabdominal aortic aneurysm (TAAA) repair, and individual bypasses were created to all visceral vessels, avoiding the risk of late patch aneurysm.
RESULTS
We identified 53 patients with LDS. Of these, 33 patients (62%) constituted the aortic surgery group. The index aortic operation was performed on 31 patients at Cleveland Clinic between September 1998 and April 2017. Some earlier patients in the series did not have the LDS diagnosis before surgery. Later, the diagnosis was confirmed with phenotype and genetic testing. Mean ages at the index operation and first aortic intervention were 39 AE 15 and 37 AE 14 years, respectively. Four patients were age 18 years or younger at the first aortic surgery.
Eleven patients (33%) in the aortic surgery group developed aortic dissection. Three patients experienced new recurrent aortic dissection, all involving the descending thoracic and thoracoabdominal aorta. One patient had a previous type II dissection repair with aortic root and total arch replacement with elephant trunk procedure. The remaining 2 patients initially experienced a DeBakey type IIIA dissection and later developed recurrent distal dissection.
Twenty of the 53 patients with LDS (38%) had not yet required aortic surgery and were managed medically, constituting the non-aortic surgery group. Their maximum aortic diameter was 3.7 cm (Table 1) . One patient in this cohort initially exhibited aortic root enlargement on yearly imaging and underwent an elective root reimplantation. For the analysis, this patient is categorized in the aortic surgery group. Patient characteristics and comorbidities are listed in Table 1 .
Operative Details
The 33 patients in the aortic surgery group underwent 58 aortic operations (Table 2 ). Six patients (20%) had previous sternotomies for acute type I dissection repair (n ¼ 3), 1 had acute type II dissection repair, 1 had aortic valve replacement, and 1 had mitral valve replacement.
Early Outcomes Operative mortality. There were no operative deaths in patients undergoing elective surgery. There were 2 urgent or emergency surgery deaths (2/33; 6%). The first patient underwent an urgent extent-II thoracoabdominal aneurysm repair. Postoperatively, she developed infarcts in left middle cerebral artery distribution followed by hemorrhagic conversion, brain-stem herniation, and death. The second patient underwent an emergency aortic arch replacement with an elephant trunk procedure for a contained rupture 
Cerebral vascular accident 6 (11) 5 (15) 1 (5)
Heart failure 3 (6) 3 (9) 0 (0)
TGFBR1, Transforming growth factor b receptor-1; TGFBR2, transforming growth factor b receptor-2; SMAD3, mothers against decapentaplegic homolog 3; TGFB2, transforming growth factor b2 ligand gene; LDS, Loeys-Dietz syndrome; CTD, connective tissue disorder; COPD, chronic obstructive pulmonary disease; ASD, atrial septal defect; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction. *This patient had confirmed LDS based on genetic testing at another institution, but details on the mutation are not available. yMedian (Q1-Q3).
of the distal ascending aorta. Postoperatively, she developed stroke in the right basal ganglia with hemorrhagic transformation and did not survive (Table E1) . Postoperative adverse events. Three postoperative strokes occurred (9%). Two patients died, as described in the preceding section. The third patient developed acute pontine infarct after a valve-sparing root reimplantation. He underwent an immediate mechanical thrombectomy of basilar artery occlusion and completely recovered. He was last seen 42 months postoperatively and was doing well.
No patients experienced myocardial infarction, heart block requiring a pacemaker, renal failure requiring dialysis, tracheotomy, hepatic dysfunction, deep venous thrombosis or pulmonary embolism, superficial or deep sternal wound infection, or sepsis. A low prevalence of other postoperative adverse outcomes was observed (Table 3) . Blood pressure control. Blood pressure control in our series was excellent (goal 130/80 mm Hg). Mean blood pressure of the entire cohort was 118 AE 16/68 AE 10 mm Hg. Of 53 patients, 30 (57%) were taking b-adrenergicblocking drugs, 5 (9%) were taking angiotensin-converting enzyme inhibitors, 31 (58%) were taking angiotensin receptor blockers, 4 (8%) were taking calcium channel blockers, and 5 (9%) were taking diuretics.
LDS and Cardiomyopathy
One patient in our series with a novel TGFBR1 mutation developed severe cardiomyopathy and underwent total aortic replacement and orthotopic heart transplantation 14 months after an initial type I aortic dissection. 2 He is doing well 8 years after his last aortic surgery. It is possible that the TGFBR1 mutation led to the microvascular dysplasia of his coronary arteries and cardiomyopathy, as noted on the pathology evaluation of the explanted heart. This association is yet to be determined.
Late Outcomes Aorta-related reoperations. Twenty-two of 33 patients (67%) in our aortic surgery group required no aortic reoperation. Indications for surgery were prophylactic aortic repair for an enlarging aortic root and ascending aortic aneurysm in 20 patients (91%) and acute type I aortic dissection in 2 patients (9%).
Valve-sparing root replacement was the prophylactic aortic operation in 95% (19/20) of these patients. Seventeen (85%) of these procedures were LGS-modified valvesparing root reimplantations performed at our institution. Two patients (10%) had valve-sparing root reimplantations performed at outside institutions. One patient with a bicuspid aortic valve (5%) required a mechanical composite valve-graft root replacement. Composite valve-graft root replacement was performed on both patients with acute type I aortic dissection. Two patients (6%) required concomitant total aortic arch replacement, 1 of whom had acute type I aortic dissection. Aortic valve repair at the time of root reimplantation was performed in 2 patients (6%). There have been no operative deaths in this subgroup.
Late outcomes of modified root reimplantation were excellent. Among the 19 patients who underwent reimplantation, there were no aortic valve-related reoperations, thromboembolism, endocarditis, or late aortic dissections. No patients developed coronary artery button aneurysms, anastomotic dehiscence, or arch aneurysm requiring reoperation. Multiple aortic operations. Multiple aortic operations were performed on 11 of 33 patients (33%). In this subgroup, 9 of the 11 patients (82%) had experienced acute aortic dissections. Overall, these patients underwent 36 aortic operations, with a mean of 3.3 aortic operations per person ( Table 4 ). The initial aortic operation was performed at another institution in 7 patients (64%). They were subsequently referred to our Aorta Center for a second or third aortic reoperation (Table E1) .
Most reoperations were for distal aortic degeneration and aneurysm formation. Total arch replacement with elephant trunk procedures were performed on 64% (7/11) of the patients requiring aortic reoperations. Overall, 18% (6/33) of patients in the aortic surgery group had total aortic replacement. All these patients had prior aortic dissection, and their arch replacements were performed at our institution. Aortic root reoperations. Four patients (12%) required reoperations on the aortic root. Two of these reoperations were for root and arch degeneration after a simple supracoronary ascending aortic replacement for type I aortic dissection. The remaining 2 root reoperations were for prosthetic aortic valve endocarditis and late structural valve deterioration of an allograft root. Estimated freedom from aorta-related reoperations among dissection and nondissection patients at 1, 5, and 10 years was 45%, 27%, and 14% versus 100%, 100%, and 86%, respectively (P <.0001; Figure 2 ).
There were 3 deaths, all in aortic surgery group. Among the 31 of 33 surviving patients, there was 1 late death, caused by a ruptured descending thoracic aortic aneurysm in a patient who had aortic root reimplantation performed at another institution 10 years previously. He was followed at our institution for a stable 3.8-cm descending thoracic aneurysm. He presented with back pain. On CTA he was found to have an expanding (5.7-cm) descending thoracic aortic aneurysm with focal dissection. He was immediately transferred to our institution, but died from aortic rupture shortly after transfer. He did not regain any vital signs despite substantial resuscitation efforts and hemodynamic support.
Overall, 33 patients in the aortic surgery cohort underwent a total of 58 aortic and 81 cardiovascular operations (Table 5) . Kaplan-Meier survival of the aortic surgery group was 89% at 10 years (number at risk ¼ 8 at 10 years; Figure 3 ). Their median follow-up was 5.2 years. Median follow-up for the non-aortic surgery group was 8.4 years. There were no deaths in this group.
Spontaneous fractures and primary inguinal, umbilical, postsurgical, and recurrent ventral hernias occur frequently in patients with LDS. In our series, 53 orthopedic and general surgical procedures were performed in our full cohort (Table 6 ). An intracranial aneurysm was identified in 20% (9/44) of our study patients who underwent CTA or MRI/MRA of the brain. Currently, all patients with LDS undergo an initial intracranial aneurysm screening as part of their cardiovascular surveillance at our institution.
Twenty patients (38%) in our series were first-degree relatives (parents, siblings, and offspring; 8 probands and 12 family members [non-probands]). Of these, 10 patients required surgical intervention: 63% of probands (5/8) and 42% of non-probands (5/12). One proband underwent an emergency aortic repair. The remaining 10 patients (4 probands, 6 non-probands) are being treated medically, with ongoing surveillance. The aortopathy was more aggressive in probands than in non-probands (Table E2) .
DISCUSSION
Since the initial description of LDS, 3 there has been significant progress in understanding the biology, phenotype, and natural history of this disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] Recently, it has been suggested that LDS be divided into 5 subtypes based on the presence of aortic aneurysm or dissection in combination with a gene mutation in TGFBR1 (LDS 1), 
TGFBR2 (LDS 2), SMAD3 (LDS 3), TGFB2 (LDS 4)
, and TGFB3 (LDS 5). 9, 10 Previous studies demonstrated that patients with LDS types 1 and 2 are at greater risk of aortic dissection and rupture at an earlier age and smaller aortic diameter. 3, 4, 16 In our series, among 11 patients who developed aortic dissections, 7 (64%) had TGFBR2 mutation, 3 (27%) had SMAD3 mutation, and 1 (9%) had TGFBR1 mutation. None of the 3 patients with TGFB2 mutation exhibited aortic dissection or rupture on presentation. This is consistent with previous reports, suggesting an aggressive nature of aortopathy in patients with TGFBR2 (LDS 2) mutation and perhaps a less aggressive phenotype in TGFB2 (LDS 4) patients. There is evidence that not all subtypes of LDS should be treated equally. In fact, patients with mutations in TGFB2 (LDS 4) might not need surgical intervention as early. 17 The decision to perform a prophylactic aortic repair in patients with LDS has been driven primarily by aortic diameter, but other considerations include rate of aortic growth, aortic valve function, phenotype, and family history.
Guidelines for medical management, clinical and radiologic surveillance, and the threshold for surgery have been suggested for these patients. 11 Initially, 4.2 cm was recommended as the threshold for performing elective operations, based on little information from a practice that has concentrated on pediatric patients. 4 However, because of the malignant natural history of the vasculopathy and established safety of prophylactic root replacement at experienced centers, recent recommendations suggest performing surgical repair of the aortic root at diameters of approximately 4.0 cm. 9 Another large, multicenter retrospective study recommended aortic surgery at 4.5 cm unless other factors suggest a more severe presentation. 18 Considering the 1 late death in our study and older reports of ''Marfanoid'' patients developing DeBakey type III dissection, earlier intervention on the descending aorta may also be warranted for many patients with LDS. 19, 20 Some groups have reported their surgical experience with LDS. 16, [21] [22] [23] Recently, Patel et al. published their series of patients with LDS who underwent cardiovascular surgery at Johns Hopkins, with excellent outcomes. 17 Their growing experience confirmed the aggressive nature of aortopathy, with a higher predisposition toward aortic catastrophe at a young age and smaller aortic diameter. A few significant differences exist between our series and their report. Our series represents the experience at most cardioaortic centers treating a largely adult population. Almost half of the patients (48%) in their series were children (age < 18 years), compared with 12% in ours, and mean age at index operation was 25 versus 39 years, respectively. Moreover, our series has a 33% prevalence of aortic dissection compared with 8% in the largely elective practice of Patel et al. 17 Aortic reintervention remains high in these patients, 36% in our cohort versus 25% in theirs, with most reinterventions due to distal aortic or arch degenerations.
Aorta-Related Reoperations
Prevalence of aorta-related reoperation is higher among patients who had initial aortic operation for an acute type I dissection. In our series, 82% (9/11) of patients who underwent multiple aortic interventions had a history of acute aortic dissection. We previously demonstrated this high risk for late and multiple aortic reoperations in other patients with connective tissue disorders. 24 In this report, 18% (6/33) of patients underwent total aortic replacement in a staged fashion, and all had a history of aortic dissection. Iba et al. 22 reported a ADULT significantly higher prevalence of total aortic replacement (40%) in patients with LDS after aortic dissection. Our current practice is not to perform routine arch replacement at the time of an elective aortic root and hemiarch replacement. In our aortic surgery cohort, no patient who underwent an elective aortic root operation developed aortic arch degeneration requiring reoperation. All are being followed with regular imaging. Our data suggest that the aggressive natural history of LDS may be modified with a timely prophylactic aortic operation.
Two of the 4 root and all arch reoperations in our series were for patients who initially presented with aortic dissection. Given the significantly high prevalence of aortic reintervention in LDS patients presenting with aortic dissection, it is justifiable to perform total arch or root replacement, or both, at the initial type I dissection repair, particularly if the patient is stable and necessary surgical expertise is available.
In our Aorta Center and the Marfan Syndrome and Connective Tissue Disorder Clinic, we stress the importance of lifelong care for these patients. Patients with a prior aortic dissection are followed more frequently. 24 In our previous report of prophylactic modified valve-sparing root repair in 178 patients with connective tissue disorders, we demonstrated safety with no operative deaths, and effectiveness with 92% freedom from aortic valve reoperation at 6 years. 25 We emphasize early prophylactic root replacement for LDS patients to avoid catastrophic vascular complications. Our modified valve-sparing root reimplantation procedure is our preferred option in these patients. 12 However, not every patient is a good candidate. Patients with significant cusp degeneration, such as calcification or multiple large fenestrations, may be better treated with composite valve-graft root replacement.
Congenital cardiac anomalies, such as mitral valve prolapse, atrial septal defect, or patent ductus arteriosus, occur frequently in patients with LDS. In our series, 2 patients underwent concomitant mitral valve surgery and root replacement; 1 patient had a concomitant atrial septal aneurysm repair. This association may be more common than previously appreciated for other connective tissue disorders as well. 26 
Role of Endovascular Therapies in Patients With LDS
Connective tissue disorders are considered a relative contraindication for endovascular aortic repair because of the risk of progressive aortic dilatation or dissection at the landing zones. It has been our practice to use endovascular techniques as a complement to open repair for patients with connective tissue disorders and specific indications for surgery. In our series, 6 patients needed endovascular repair. Two had emergency TEVAR for malperfusion, and 2 underwent intervention for an intercostal patch aneurysm and iliac artery aneurysm after previous open TAAA repair. The last 2 patients underwent TEVAR for urgent second-stage elephant trunk and because of a hostile abdomen from recent spontaneous colonic perforations. 27 One patient will likely require an open TAAA repair. 24, 28 LDS is a lifelong disease, and endovascular therapies are important adjuncts to open repair, especially for aortic dissections, ruptures, and peripheral vascular aneurysms. As reported by others, 29 it is reasonable to perform an endovascular repair Valve-sparing root reimplantation þ mitral valve/ atrial septal aneurysm repair of a localized segment of aorta when both the proximal and distal landing zones lie within a surgical graft.
Noncardiovascular Manifestations
A recent study reported that 60% of patients with LDS had low bone mineral density in the spine, hip, or femoral neck. There is a 50% risk of developing fractures by 14 years of age in patients with LDS types 1 and 2. 30 Other lifethreatening conditions include splenic and bowel rupture requiring surgery. 4 Our experience suggests that patients with LDS should be counseled about the high occurrence of noncardiovascular complications and risk of fractures.
CONCLUSIONS
Loeys-Dietz syndrome carries a malignant prognosis, with early presentation of dissection and rapid progression of aneurysmal dilatation if not treated before dissection occurs. A multidisciplinary approach and close collaboration between cardiologists, cardiovascular surgeons, and geneticists is essential for early recognition, close surveillance, and timely prophylactic surgery on these patients to prevent catastrophic complications. Physicians should consider the syndrome when patients exhibit aortic dilatation at a young age and variable connective tissue findings appear ''Marfanoid'' and may overlap with Marfan syndrome. Early referral to a high-volume center with expertise in the care of patients with aortic disease may result in more favorable outcomes.
Webcast
You can watch a Webcast of this AATS meeting presentation by going to: https://aats.blob.core.windows.net/media/18 May01/28ABC%202.Aortic%20Endovascular/S86%20-% 20Part%202/S86_3_webcast_043552738.mp4.
Conflict of Interest Statement
M.A. is a consultant for Biom'Up and a member of the Clinical Events Committee; C.M.R. is a consultant for Ambry Genetics and My Gene Counsel; E.E.R., is a speaker and consultant for Medtronic, St. Jude Medical, LivaNova, Cook Medical, Bolton Medical, and Terumo; L.G.S. receives royalties for inventions or discoveries commercialized through Posthorax GmbH and is an unpaid member of the Executive Committee for PARTNER trials I and II and the COMMENCE trial, which are sponsored by Edwards Lifesciences. All other authors have nothing to disclose with regard to commercial support. 
Discussion
Dr Duke Cameron (Baltimore, Md). Mr Cikach, thank you for an excellent presentation summarizing your institution's experience with Loeys-Dietz syndrome. Because the disease is rare and was only recognized 13 years ago, it is clear there is still a lot to learn about its features, the various subtypes, the natural history, and its response to our interventions. With the discovery of any new disease, there is a tendency for the most severe phenotype to be described first, which can lead to an exaggerated view of its aggressiveness. In the case of Loeys-Dietz syndrome, those initial suspicions about severity have been borne out, at least for certain subtypes.
I agree very much with all of your major findings and recommendations, which are that prophylactic surgery is low risk; valve-sparing procedures are usually appropriate and successful; reinterventions are common, especially in the setting of dissection; these patients need very close surveillance; and finally, that endovascular interventions really have a limited role. I have 2 very simple, straightforward questions for you.
You point out that you routinely screen for intracranial aneurysms and have identified them in 20% of your patients. What do you do with that information? Have you intervened on any patients with aneurysm and what are the criteria for intervention?
Mr Cikach (Cleveland, Ohio). Most of the intracranial aneurysms in our series were quite small. We did refer to neurosurgery for those aneurysms, but I think a very low rate of those were actually intervened upon. Dr Cameron. Very good. The second question concerns routine arch replacement at the time of root surgery. You do not recommend concomitant arch replacement because in your experience dissection. We replaced her aorta, we thought things were looking pretty good, and then she died in her late 20s after we had replaced everything we thought could be aneurysmal; she ruptured a medium-size vessel that happened to be very tortuous.
So, again, with people who present at a younger age, not only should we consider being more aggressive about the arch and the aorta as Duke suggested, but we should also be more aggressive in our imaging surveillance.
Dr Svensson. Eric, you touched on an important point that Duke was also bringing up. The greater vessels in these patients are at a much greater risk of developing aneurysms than in patients with Marfan syndrome. If you are going to do individual bypasses to the greater vessels, make sure your anastomosis is absolutely waterproof before you progress, because it is going to be difficult to get back to those very fragile tissues. It is like the Ehlers-Danlos patient: Use 5-0 or 6-0 with small pledgets of interrupted sutures on the back wall, because you are not going to be able to go back in. If you try, you risk everything falling apart.
Dr Roselli. Great. Thank you. If anyone wants to speak to Dr Aftab afterward, I am going to offer him to be available. Great job, Frank.
Readers who found these articles interesting may also like to read the following papers found in recent and future issues of our sister publications, Seminars in Thoracic and Cardiovascular Surgery and Operative Techniques in Thoracic and Cardiovascular Surgery! SMAD3, Mothers against decapentaplegic homolog 3; AsAR, ascending aortic replacement; TAR, total arch replacement; TEVAR, thoracic endovascular aortic repair; TAAA, thoracoabdominal aortic aneurysm; AD (I), aortic dissection type-I; DTAA, descending thoracic aortic aneurysm; AV, aortic valve; VSRR, valve-sparing root repair; TAR, total arch replacement; AD (II), aortic dissection type-II; ARA, aortic root aneurysm; AI, aortic insufficiency; PFO, patent foramen ovale; ArcA, arch aneurysm; TGFBR2, transforming growth factor b receptor-2; M-CVG, mechanical composite valve-graft replacement; ET, elephant trunk; AAA, abdominal aortic aneurysm; DTA, descending thoracic aorta; ARR, aortic root replacement; AsAA, ascending aortic aneurysm; HAR, hemiarch replacement; AD (III), aortic dissection type-III; SMA, superior mesenteric artery; VA, vertebral artery; B-CVG, bioprosthetic composite valve-graft replacement; EVAR, endovascular aortic repair; SCvA, subclavian artery; CA, carotid artery; TCT, thyrocervical trunk; OHT, orthotopic heart transplantation; CABG, coronary artery bypass grafting; DCMP, dilated cardiomyopathy; AD (IIIA), aortic dissection type-IIIA; AD (IIIB), aortic dissection type-IIIB; AxA, axillary artery; ITA, internal thoracic artery; PSA, pseudoaneurysm; CAD, coronary artery disease; CEA, carotid endarterectomy; AVR, aortic valve replacement. *LDS confirmed with genetic testing at outside hospital. 
